2026-06-14T03:30:03Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/203022024-11-28T21:22:43Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Garcia Recio, Marta author Martinez-Serra, Jordi author Bento, Leyre author Ramos-Asensio, Rafael author Gines, Jordi author Daumal-Domenech, Jaume author Sampol Mayol, Antonia author Gutierrez, Antonio 2024-07-09T09:14:31Z 2024-07-09T09:14:31Z 2016 Garcia Recio M, Martinez Serra JJ, Bento L, Ramos Asensio R, Gines J, Daumal J, et al. Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report. OncoTargets Ther. 2016;9. 10.2147/OTT.S107893 1178-6930 Oncotargets and Therapy http://hdl.handle.net/20.500.13003/17182 27660468 L612301291 2-s2.0-84988892513 http://hdl.handle.net/20.500.12105/20302 383159100001 Blastic plasmocytoid dendritic cell neoplasm is characterized by aggressive behavior with a tendency for systemic dissemination and a predilection for skin, lymph nodes, soft tissues, peripheral blood, or bone marrow. It usually occurs in elderly patients with a mean age between 60 and 70 years. Despite initial response to chemotherapy, the disease regularly relapses with a short median overall survival. Better outcomes have been reported with high-dose acute leukemia-like induction chemotherapy followed by consolidation with allogeneic hematopoietic stem cell transplantation. However, elderly patients are not candidates for intensive therapy or allogeneic stem cell transplantation. So, new active and tolerable drugs are needed. Our case illustrates that one cycle of lenalidomide and celecoxib provides at least a partial cutaneous and hematologic response, but this regimen was discontinued due to toxicity and followed by a consolidation/maintenance phase with azacitidine, thus achieving a final complete response with a much higher than expected progression-free and overall survival in an elderly patient with comorbidities. This information may be useful in the design of treatment approaches for elderly patients with blastic plasmocytoid dendritic cell neoplasm. However, it should be confirmed in clinical trials as well as by optimizing the induction and extending the consolidation/maintenance period to avoid early relapses after discontinuation and improve progression-free survival. eng Blastic plasmocytoid dendritic cell neoplasm Elderly Immunomodulatory COX-2 Hypomethylating Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report research article